NHWA(SZ:002262) Xin Lang Cai Jing·2025-03-29 01:33Group 1 - Enhua Pharmaceutical (002262.SZ) released its 2024 annual report on March 29, 2025, indicating that as of March 28, 2025, 162 institutional investors disclosed holding A-shares, totaling 438 million shares, which accounts for 43.14% of the total share capital [1] - The top ten institutional investors include Xuzhou Enhua Investment Co., Ltd., Hong Kong Central Clearing Limited, and several funds, with the top ten collectively holding 38.60% of the shares, a decrease of 1.15 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one fund, Morgan Stanley's Yuyao Anhe Mixed A, increased its holdings, while eight funds, including China Europe Medical Health Mixed A and others, reduced their holdings, with a total decrease of 1.16% [2] - A total of 127 new public funds were disclosed this period, including several from Invesco Great Wall and others, while 33 funds were not disclosed this period, including various funds from Huatai-PineBridge [2] - Foreign investment sentiment showed a decrease in holdings from one foreign fund, Hong Kong Central Clearing Limited, with a reduction of 0.36% [2]